lonafarnib has been researched along with paclitaxel in 16 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 31,874 | 5,729 | 15,395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (12.50) | 18.2507 |
| 2000's | 11 (68.75) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bishop, WR; Izbicka, E; Lawrence, RA; Petit, T; Von Hoff, DD; Weitman, S | 1 |
| Bishop, WR; Chen, J; Ferrari, E; Gurnani, M; Hajian, G; Lipari, P; Liu, M; Malkowski, M; Nielsen, LL; Shi, B; Yaremko, B | 1 |
| Bishop, WR; Hajian, G; Liu, M; Nielsen, LL; Shi, B; Terracina, G; Yaremko, B | 1 |
| Casciano, CN; Clement, RP; Johnson, WW; Wang, E | 1 |
| Adjei, AA; Dy, GK | 1 |
| Bangert, S; Bishop, WR; Fossella, FV; Glisson, BS; Herbst, RS; Hong, WK; Khuri, FR; Kies, MS; Kim, ES; Kirschmeier, P; Lu, C; Meyers, ML; Munden, RF; Papadimitrakopoulou, V; Shin, DM; Statkevich, P; Tendler, C; Thall, PF; Thompson, E; Wang, XM; Zhu, Y | 1 |
| El-Naggar, A; Giannakakou, P; Hamel, E; Khuri, FR; Marcus, AI; Nivens, M; O'Brate, A; Wong, J; Yao, TP; Zhou, J | 1 |
| Appels, NM; Beijnen, JH; Rosing, H; Schellens, JH; van Maanen, MJ | 1 |
| Fossella, FV; Glisson, BS; Khuri, FR; Kies, MS; Kim, ES; Munden, RF; Papadimitrakopoulou, V; Pisters, KM; Rogatko, A; Statkevich, P; Summey, C; Tighiouart, M; Zaknoen, S | 1 |
| Bukowski, RM; Curtis, D; Frank, E; Lipton, A; Ready, NE; Statkevich, P; Zhu, Y | 1 |
| Bishop, WR; Kirschmeier, P; Liu, G; Liu, M; Long, BJ; Marrinan, CH; Nale, L; Taylor, SA | 1 |
| Giannakakou, P; Gjyrezi, A; Khuri, FR; Tamanoi, F; Vos, CC; Yoshida, M; Zhou, J | 1 |
| Adema, AD; Honeywell, RJ; Peters, GJ; van der Born, K | 1 |
| Baumann, K; Belau, A; Burges, A; Canzler, U; du Bois, A; Gropp-Meier, M; Huober, J; Kreienberg, R; Meier, W; Rau, J; Richter, B; Schmalfeldt, B; Schröder, W; Sehouli, J; Stähle, A; Wimberger, P; Wollschlaeger, K | 1 |
| Awada, A; Beijnen, JH; Diéras, V; Govaerts, AS; Huitema, AD; Kerklaan, BM; Le Tourneau, C; Marreaud, S; Mergui-Roelvink, M; Milojkovic Kerklaan, B; Piccart-Gebhart, MJ; Rosing, H; Schellens, JH | 1 |
| Aminossadati, B; Bachmann, HS; Burges, A; du Bois, A; Hillemanns, P; Huober, J; Kimmig, R; Kuhlmann, JD; Meier, W; Schmalfeldt, B; Sehouli, J; Siffert, W; Wimberger, P; Wollschlaeger, K | 1 |
1 review(s) available for lonafarnib and paclitaxel
| Article | Year |
|---|---|
Farnesyltransferase inhibitors in breast cancer therapy.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Clinical Trials as Topic; Deoxycytidine; Drug Screening Assays, Antitumor; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Female; Fluorouracil; Humans; Mice; Neoplasm Proteins; Paclitaxel; Piperidines; Protein Prenylation; Protein Processing, Post-Translational; Pyridines; Quinolones; Signal Transduction; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2002 |
6 trial(s) available for lonafarnib and paclitaxel
| Article | Year |
|---|---|
Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Anemia; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Dose-Response Relationship, Drug; Farnesyltranstransferase; Fatigue; Female; Heart Arrest; Humans; Leukopenia; Male; Middle Aged; Neoplasms; Neutropenia; Paclitaxel; Piperidines; Pyridines; Treatment Outcome | 2004 |
Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.
Topics: Adult; Aged; Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Bridged-Ring Compounds; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Staging; Paclitaxel; Piperidines; Pyridines; Remission Induction; Survival Rate; Taxoids; Treatment Outcome | 2005 |
Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Clinical Trials as Topic; Dose-Response Relationship, Drug; Enzyme Inhibitors; Farnesyltranstransferase; Female; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Paclitaxel; Piperidines; Pyridines; Time Factors | 2007 |
Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Ovarian Epithelial; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Staging; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Paclitaxel; Piperidines; Prospective Studies; Pyridines; Survival Analysis; Young Adult | 2012 |
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Dose-Response Relationship, Drug; Female; Humans; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Piperidines; Pyridines; Receptor, ErbB-2; Trastuzumab; Treatment Outcome | 2013 |
The FNTB promoter polymorphism rs11623866 as a potential predictive biomarker for lonafarnib treatment of ovarian cancer patients.
Topics: Adult; Aged; Alleles; Antineoplastic Agents; Carboplatin; Farnesyltranstransferase; Female; Genetic Markers; Genotype; Humans; Kaplan-Meier Estimate; Middle Aged; Ovarian Neoplasms; Paclitaxel; Piperidines; Polymorphism, Genetic; Promoter Regions, Genetic; Protein Subunits; Pyridines; Treatment Outcome; Young Adult | 2015 |
9 other study(ies) available for lonafarnib and paclitaxel
| Article | Year |
|---|---|
Activity of SCH 66336, a tricyclic farnesyltransferase inhibitor, against human tumor colony-forming units.
Topics: Alkyl and Aryl Transferases; Cell Survival; Cisplatin; Clone Cells; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Neoplasm; Etoposide; Farnesyltranstransferase; Humans; Neoplasms; Neoplastic Stem Cells; Paclitaxel; Piperidines; Pyridines; Sensitivity and Specificity; Tumor Cells, Cultured; Tumor Stem Cell Assay | 1999 |
Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
Topics: Adenocarcinoma; Adenoviruses, Human; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Survival; Drug Synergism; Female; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, SCID; Mice, Transgenic; Ovarian Neoplasms; Paclitaxel; Pancreatic Neoplasms; Piperidines; Prostatic Neoplasms; Pyridines; Teratocarcinoma; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 1999 |
The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
Topics: Alkyl and Aryl Transferases; Animals; Antineoplastic Agents, Phytogenic; Cell Division; Docetaxel; Drug Synergism; Enzyme Inhibitors; Female; Gene Expression Regulation, Neoplastic; Genes, ras; Humans; Male; Mice; Mice, Nude; Mice, Transgenic; Paclitaxel; Piperidines; Pyridines; Taxoids; Tumor Cells, Cultured; Tumor Suppressor Protein p53 | 2000 |
The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
Topics: 3T3 Cells; Adenosine Triphosphate; Alkyl and Aryl Transferases; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Cell Line; CHO Cells; Cricetinae; Daunorubicin; Drug Synergism; Enzyme Inhibitors; Farnesyltranstransferase; Genes, MDR; Humans; Hydrolysis; Mice; Paclitaxel; Piperidines; Pyridines; Rhodamine 123; Tamoxifen; Vinblastine | 2001 |
The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Topics: Acetylation; Alkyl and Aryl Transferases; Animals; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cell Death; Cell Line, Tumor; Drug Synergism; Farnesyltranstransferase; Histone Deacetylase 6; Histone Deacetylase Inhibitors; Histone Deacetylases; Humans; Lung Neoplasms; Mice; Microtubules; Mitosis; NIH 3T3 Cells; Paclitaxel; Piperidines; Pyridines; Tubulin | 2005 |
Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Topics: Administration, Oral; Alkyl and Aryl Transferases; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Drug Therapy, Combination; Enzyme Inhibitors; Farnesyltranstransferase; Humans; Injections, Intravenous; Molecular Structure; Paclitaxel; Piperidines; Pyridines; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Trastuzumab | 2005 |
Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Biomarkers, Tumor; Cell Cycle; Cell Growth Processes; Cell Line, Tumor; Dose-Response Relationship, Drug; Drug Synergism; Farnesyltranstransferase; Female; HSP40 Heat-Shock Proteins; Humans; Leukocytes, Mononuclear; Mice; Mice, Nude; Mice, SCID; Ovarian Neoplasms; Paclitaxel; Piperidines; Pyridines; Xenograft Model Antitumor Assays | 2008 |
The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.
Topics: Alkyl and Aryl Transferases; Antineoplastic Agents, Phytogenic; Cell Line; Cell Line, Tumor; Cell Proliferation; Cytoplasm; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Histone Deacetylase 6; Histone Deacetylases; Humans; Microtubules; Models, Biological; Paclitaxel; Piperidines; Pyridines; Time Factors | 2009 |
Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.
Topics: Animals; Antineoplastic Agents, Alkylating; Carcinoma, Non-Small-Cell Lung; Cell Cycle; Cell Line, Tumor; Dacarbazine; Deoxycytidine; Deoxyguanosine; DNA Adducts; DNA Methylation; Drug Synergism; Gemcitabine; Humans; Lung Neoplasms; Mice; O(6)-Methylguanine-DNA Methyltransferase; Paclitaxel; Piperidines; Pyridines; Temozolomide | 2009 |